Sara Johnson Davis is an accomplished Advocacy and Government Relations Executive with more than two decades of leadership in the biotechnology and pharmaceutical industries. She specializes in patient advocacy, government affairs, coalition building, and health equity, with a proven track record of shaping policy and amplifying the patient voice across the healthcare ecosystem.
In her current role as Vice President, Head of Patient Advocacy & Policy at Fulcrum Therapeutics, Sara leads global efforts to strengthen partnerships with the rare disease and sickle cell communities, ensuring that patient perspectives guide Fulcrum’s strategy, clinical development, and policy initiatives.
Prior to joining Fulcrum, Sara served as Senior Director of Patient Advocacy at Editas Medicine, where she led engagement strategies to elevate patient and caregiver insights in advancing gene-editing innovation for sickle cell disease and beta thalassemia. She has also held senior advocacy and policy positions at CRISPR Therapeutics and Novartis, where she developed and implemented comprehensive advocacy and legislative strategies across multiple therapeutic areas.
Renowned for her ability to build strategic partnerships, influence health policy, and integrate the patient voice into corporate and clinical decision-making, Sara brings deep expertise in Medicaid policy, access, rare diseases, genetic therapies, and equitable access to care. Her work reflects a career-long commitment to ensuring that innovation in medicine is shaped with and for the patients it serves.
